[Whole body positron emission tomography in breast cancer].
The value of whole body positron emission tomography using F-18 2-deoxy-2-fluoro-d-glucose in primary work-up and follow-up was prospectively evaluated in 37 patients with primary or metastatic breast cancer. From 20 primary breast masses 15 from 16 malignant and 4 from 4 benign lesions confirmed by biopsy, were detected. In 3 out of 21 patients in correlation to morphologic imaging, respectively biopsy, no metastatic disease was not identified. Generally speaking, whole body positron emission tomography appears to be a suitable diagnostic staging tool in breast cancer.
Nitzsche
E U
EU
Department of Radiological Science, UCLA School of Medicine.
Hoh
C K
CK
Dalbohm
N M
NM
Glaspy
J A
JA
Phelps
M E
ME
Moser
E A
EA
Hawkins
R A
RA
D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000453:epidemiology / Q000556:secondary; D000232:Adenofibroma / Q000000981:diagnostic imaging* / Q000453:epidemiology / Q000556:secondary; D000293:Adolescent; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000453:epidemiology / Q000556:secondary; D002277:Carcinoma / Q000000981:diagnostic imaging* / Q000453:epidemiology / Q000556:secondary; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000000981:diagnostic imaging* / Q000453:epidemiology / Q000556:secondary; D003847:Deoxyglucose / Q000031:analogs & derivatives; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D014055:Tomography, Emission-Computed / Q000379:methods*
D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose